Compare HY & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HY | ACHV |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.1M | 618.0M |
| IPO Year | 2012 | 2018 |
| Metric | HY | ACHV |
|---|---|---|
| Price | $31.86 | $6.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 84.1K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,769,300,000.00 | N/A |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.41 | $2.38 |
| 52 Week High | $44.55 | $7.11 |
| Indicator | HY | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 66.70 |
| Support Level | $29.88 | $4.09 |
| Resistance Level | $34.57 | N/A |
| Average True Range (ATR) | 1.78 | 0.46 |
| MACD | -0.55 | 0.09 |
| Stochastic Oscillator | 7.15 | 71.83 |
Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.